Regeneron Pharmaceuticals Inc (REGN) - Total Assets
Based on the latest financial reports, Regeneron Pharmaceuticals Inc (REGN) holds total assets worth $40.87 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Regeneron Pharmaceuticals Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Regeneron Pharmaceuticals Inc - Total Assets Trend (1990–2025)
This chart illustrates how Regeneron Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See REGN book value for net asset value and shareholders' equity analysis.
Regeneron Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Regeneron Pharmaceuticals Inc's total assets of $40.87 Billion consist of 44.4% current assets and 55.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.7% |
| Accounts Receivable | $5.74 Billion | 14.2% |
| Inventory | $3.20 Billion | 7.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.26 Billion | 3.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1990–2025)
This chart illustrates how Regeneron Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Regeneron Pharmaceuticals Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regeneron Pharmaceuticals Inc's current assets represent 44.4% of total assets in 2025, a decrease from 88.2% in 1990.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2025, down from 85.8% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 14.2% of total assets.
Regeneron Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Regeneron Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Jinyu Bio-Technology Co Ltd
SHG:600201
|
China | CN¥6.54 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Regeneron Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.57 | 4.93 | 3.57 |
| Quick Ratio | 2.96 | 4.03 | 3.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $13.10 Billion | $14.01 Billion | $9.61 Billion |
Regeneron Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Regeneron Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.06 |
| Latest Market Cap to Assets Ratio | 1.59 |
| Asset Growth Rate (YoY) | 7.4% |
| Total Assets | $40.56 Billion |
| Market Capitalization | $64.60 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Regeneron Pharmaceuticals Inc's assets above their book value (1.59x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Regeneron Pharmaceuticals Inc's assets grew by 7.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Regeneron Pharmaceuticals Inc (1990–2025)
The table below shows the annual total assets of Regeneron Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $40.56 Billion | +7.41% |
| 2024-12-31 | $37.76 Billion | +14.15% |
| 2023-12-31 | $33.08 Billion | +13.23% |
| 2022-12-31 | $29.21 Billion | +14.86% |
| 2021-12-31 | $25.43 Billion | +48.19% |
| 2020-12-31 | $17.16 Billion | +15.93% |
| 2019-12-31 | $14.81 Billion | +26.17% |
| 2018-12-31 | $11.73 Billion | +33.89% |
| 2017-12-31 | $8.76 Billion | +25.68% |
| 2016-12-31 | $6.97 Billion | +24.32% |
| 2015-12-31 | $5.61 Billion | +44.87% |
| 2014-12-31 | $3.87 Billion | +31.20% |
| 2013-12-31 | $2.95 Billion | +41.84% |
| 2012-12-31 | $2.08 Billion | +57.19% |
| 2011-12-31 | $1.32 Billion | +21.49% |
| 2010-12-31 | $1.09 Billion | +46.98% |
| 2009-12-31 | $741.20 Million | +10.62% |
| 2008-12-31 | $670.04 Million | -28.43% |
| 2007-12-31 | $936.26 Million | +60.02% |
| 2006-12-31 | $585.09 Million | +38.16% |
| 2005-12-31 | $423.50 Million | -10.49% |
| 2004-12-31 | $473.11 Million | -1.34% |
| 2003-12-31 | $479.56 Million | +22.47% |
| 2002-12-31 | $391.57 Million | -20.96% |
| 2001-12-31 | $495.40 Million | +137.86% |
| 2000-12-31 | $208.27 Million | +52.02% |
| 1999-12-31 | $137.00 Million | -12.68% |
| 1998-12-31 | $156.90 Million | -6.83% |
| 1997-12-31 | $168.40 Million | +22.38% |
| 1996-12-31 | $137.60 Million | +46.70% |
| 1995-12-31 | $93.80 Million | -0.42% |
| 1994-12-31 | $94.20 Million | -19.90% |
| 1993-12-31 | $117.60 Million | +20.12% |
| 1992-12-31 | $97.90 Million | -14.12% |
| 1991-12-31 | $114.00 Million | +348.82% |
| 1990-12-31 | $25.40 Million | -- |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more